Products Omalizumab is commercially available as a powder and solvent for solution for injection (Xolair). It has been approved in many countries since 2006. Structure and properties Omalizumab is a recombinant, humanized monoclonal antibody with a molecular weight of approximately 149 kDa. Effects Omalizumab (ATC R03DX05) has antiallergic and antiasthmatic properties. The effects are based … Omalizumab
Products Pembrolizumab was approved as an infusion product in the United States in 2014 and in the EU and many countries in 2015 (Keytruda). Structure and properties Pembrolizumab is a humanized monoclonal antibody. It is an IgG4-κ immunoglobulin with a molecular weight of approximately 149 kDa. Effects Pembrolizumab (ATC L01XC18) has antitumor and immunomodulatory properties. … Pembrolizumab
Products Emicizumab was approved in the United States in 2017 and in the EU and many countries in 2018 as a subcutaneous solution for injection (Hemlibra). Structure and properties Emicizumab is a humanized and modified bispecific IgG4 monoclonal antibody that binds Factor IXa and Factor X. It is a human antibody. It has a molecular … Emicizumab
Products Reslizumab was approved in the United States and EU in 2016 and in many countries in 2017 as a concentrate for the preparation of an infusion solution (Cinqaero). Structure and properties Reslizumab is a humanized IgG4/κ monoclonal antibody produced by biotechnological methods. The molecular mass is approximately 147 kDa. Effects Reslizumab (ATC R03DX08) binds … Reslizumab
Products Blinatumomab is commercially available as an infusion product (Blincyto). It has been approved in the United States since 2014, in the EU since 2015, and in many countries since 2016. Structure and properties Blinatumomab is an antibody construct (fusion protein) of 504 amino acids with a molecular weight of approximately 54 kDa. It consists … Blinatumomab
Products Necitumumab was approved as an infusion solution in the United States in 2015 and in the EU in 2016 (Portrazza). Necitumumab has not yet been registered in many countries. Structure and properties Necitumumab is a recombinant human IgG1 monoclonal antibody. It is produced by biotechnological methods. Effects Necitumumab has antitumor, antiproliferative, and antiangiogenic properties. … Necitumumab
Products Isatuximab was approved in many countries, in the EU, and in the United States in 2020 as a concentrate for the preparation of an infusion solution (Sarclisa). Structure and properties Isatuximab is a chimeric monoclonal antibody derived from IgG1. It is produced by biotechnological methods. The molecular mass is approximately 148 kDa. Effects Isatuximab … Isatuximab
Products Dinutuximab was approved in the United States and the EU in 2015 as a concentrate for the preparation of an infusion solution (Unituxin). It has not yet been registered in many countries. Structure and properties Dinutuximab is a chimeric monoclonal antibody (human/mouse). Effects Dinutuximab (ATC L01XC16) has cytotoxic properties. It binds to ganglioside GD2, … Dinutuximab
Products Ixekizumab was approved in the United States, the EU, and many countries in 2016 as a solution for injection in a prefilled pen and syringe (Taltz). Structure and properties Ixekizumab is a humanized IgG4 monoclonal antibody with a molecular mass of 146 kDa produced by biotechnological methods. Effects Ixekizumab (ATC L04AC13) has immunosuppressive and … Ixekizumab
Products Bezlotoxumab was approved in the United States and EU in 2016 and in many countries in 2017 as a concentrate for the preparation of an infusion solution (Zinplava). Structure and properties Bezlotoxumab (ATC J06BB21) is an IgG1 monoclonal antibody with a molecular weight of 148.2 kDa. It is produced by biotechnological methods. Effects Bezlotoxumab … Bezlotoxumab
Products Canakinumab is commercially available as a powder for solution for injection (Ilaris). It has been approved in many countries since 2009. Structure and properties Canakinumab is a recombinant human IgG1κ monoclonal antibody produced by biotechnological methods. Effects Canakinumab (ATC L04AC08) has anti-inflammatory properties. The effects are based on binding to interleukin-1β (IL-1β). This reduces … Canakinumab
Products Palivizumab is commercially available as an injectable (Synagis). It has been approved in many countries since 1999. Structure and properties Palivizumab is a humanized IgG1k monoclonal antibody with a molecular mass of 148 kDa that binds to respiratory syncytial virus (RSV). The drug target is A-epitope of the fusion protein (F-protein) on the surface … Palivizumab
